Alopecia Areata. Alopecia areata
Conditions
Interventions
Intervention 1: Intervention group:children aged 2 to 18 years with alopecia areata receiving tofacitinib. Intervention 2: Intervention group: children aged 2 to 18 years with alopecia areata receivin
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
2 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1) SALT score above 20% 2) Consent of the child's parent and signing of the consent form to enter the clinical trial 3) Possibility of regular follow-up in the clinic
Exclusion criteria
Exclusion criteria: Existence of underlying systemic diseases Parents' lack of satisfaction with systemic treatment SALT score lower than 20
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of the effects of Baricitinib and Tofacitinib in pediatric patients with alopecia areata. Timepoint: The beginning of the study, 1 month later, 3 months later and 6 months later. Method of measurement: According to clinical examination and SALT score. | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of the effects of baricitinib and tofacitinib in pediatric patients with alopecia areata. Timepoint: The beginning of the study, one month later, three months later and six months later. Method of measurement: Clinical examination and SALT score. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAlireza Banani
Tehran University of Medical Sciences
Outcome results
None listed